FR-901228: Fujisawa/National Cancer Institute

Current Opinion in Investigational Drugs

Volumn 3, Issue 9, 2002, Pages 1396-1402

  Vigushin, David M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; CISPLATIN; CR 994; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FR 901228; HISTONE DEACETYLASE INHIBITOR; MITOMYCIN C; RETINOIC ACID; UNCLASSIFIED DRUG; VINCRISTINE; VORINOSTAT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG ISOLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG UTILIZATION; ENZYME ACTIVITY; FATIGUE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE NECROSIS; HUMAN; HYPOCALCEMIA; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; ONCOGENE; PHARMACODYNAMICS; REVIEW; SOLID TUMOR; STEADY STATE; STOMACH CARCINOMA; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; THROMBOCYTOPENIA; UNITED STATES; VOMITING;

ANIMALS; CLINICAL TRIALS; DEPSIPEPTIDES; DRUG INDUSTRY; HISTONE DEACETYLASES; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; PEPTIDES, CYCLIC; UNITED STATES;

EID: 0036771408     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. 159274 FR-901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no 968: I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumour activity. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M J Antibiot (Tokyo) 1994 47 3 301-310 First report describing purification of FR-901228, including data on its antitumor in vitro and in vivo activity.
2. 159275 FR-901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968: II. Structure determination. Shigematsu N, Ueda H, Takase S, Tanaka H, Yamamoto K, Tada T J Antibiot (Tokyo) 1994 47 3 311-314
3. 159276 FR-901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no 968: III. Antitumor activities on experimental tumors in mice. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K3 J Antibiot (Tokyo) 1994 47 3 315-323
4. 175383 Effects of infusion rate on the toxicity of depsipeptide (NSC-630176) in beagle dogs. Page JP, Rodman LE, Heath JE Proc Annu Meet Am Assoc Cancer Res 1995 36 Abs 2193
5. 192361 Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no 968, on Ha-ras transformed NIH3T3 cells. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M Biosci Biotech Biochem 1994 58 9 1579-1583 Data showing that reversion of transformed morphology and reduction in c-myc expression by FR-901228 correlates with growth inhibition and cell cycle arrest of murine fibroblasts.
6. 192375 Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE Mol Pharmacol 1994 46 4 627-638
7. 294304 Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS. Chan KK, Bakhtiar R, Jiang C Invest New Drugs 1997 15 3 195-206
8. 326142 Histone deacetylase inhibitors induce mitotic arrest in human cancer cells, disrupting kinetochores and centrosomes. Sackett DL, Bates SE, Robbins AR Proc Annu Meet Am Assoc Cancer Res 1999 40 Abs 4106
9. 327439 Drug development pipeline: FR-901228. Fujisawa Pharmaceutical Co Ltd Company Communication 1999 June 10 Confirmation that FR-901228 is under joint development with the NCI.
10. 350509 In vivo treatment of human acute promyelocytic leukemia with a histone deacetylase inhibitor, FR-901228. Kosugi H, Towatari M, Ito M, Ito M, Saito H, Naoe T Blood 1999 94 10 Suppl 1 Abs 2261
11. 395182 Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. Kim YB, Ki SW, Yoshida M, Horinuchi S J Antibiot (Tokyo) 2000 53 10 1191-1200
12. 406109 Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. Warrell RP, He LZ, Richon V, Calleja E, Pandolfi PP J Natl Cancer Inst 1998 90 21 1621-1625 First report of successful treatment of APL in vivo by combination therapy with an HDAC inhibitor (phenylbutyrate) and ATRA.
13. 410694 Histone deacytelase inhibitor for the treatment of peripheral or cutaneous T-cell lymphoma. Piekarz R, Robey R, Bakke S, Sandor V, Wilson W, Bates S Proc Am Soc Clin Oncol 2001 20 Pt 2 Abs 2680 Antitumor efficacy of FR-901228 in patients with PTCL and CTCL.
14. 433293 Potential value of the histone deacetylase inhibitor depsipeptide (FR901228) in the treatment of peripheral and cutaneous T-cell lymphoma. Piekarz P, Robey R, Sandor V, Fojo AT, Bakke S, Wilson W, Kingma D, Turner M, Tucker E, Bates SE AACR NCI EORTC Mol Targets Cancer Ther 2001 October 29-November 2 Abs 360 Additional report on the antitumor activity of FR-901228 against PTCL and CTCL.
15. 451672 Analysis of molecular markers and targets in trials of depsipeptide, FR901228, a histone deacetylase inhibitor with clinical activity in T-cell lymphoma. Piekarz R, Robey R, Fojo T, Bakke S, Wilson W, Jaffe E, Turner M, Cannon R, Bates SE Proc Am Soc Clin Oncol 2002 21 1 Abs 88 Phase II data on FR-901228 in PTCL and CTCL.
16. 452248 American Society of Clinical Oncology - 38th Annual Meeting (Part VII), Orlando, FL, USA. Evans L IDDB Meeting Report 2002 May 18-21
17. 452556 A phase I study to determine minimally effective pharmacologic dose of depsipeptide (FR901228) in selected hematologic malignancies. Bruner RJ, Marcucci G, Binkley P, Fischer B, Parthun M, Davis M, Xiao J, Chan K, Wright J, Grever MR, Byrd JC Proc Am Soc Clin Oncol 2002 21 1 Abs 1059 This phase I study of FR-901228 showed some partial responses in CLL patients, but no benefit for AML patients.
18. 457827 Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Kwon HJ, Kim MS, Kin MJ, Nakajima H, Kim KW Int J Cancer 2002 97 3 290-296 Report detailing evidence that FR-901228 inhibits tumor angiogenesis in vitro and in vivo, possibly via gene transcription.
19. 457831 Sequential 5-aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong ONP, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH J Immunother 2001 24 2 151-161 Combination of FR-901228 and DAC induces apoptosis and enhances expression of tumor antigens in human lung cancer cells but not normal bronchial epithelial cells.
20. 457832 Depsipeptide (FR901228) induces lysine-specific histone acetylation, differentiation and apoptosis in acute myeloid leukemia cells and demonstrates synergy with decitabine. Maghraby EA, Murphy T, Parthun MR, Klisovic M, Sklenar A, Archer KJ, Whitman S, Grever MR, Caligiuri MA, Byrd JC, Marcucci G Blood 2001 98 11 Part 1 103a-104a
21. 457837 Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. Murata M, Towatari M, Kosugi H, Tanimoto M, Ueda R, Saito H, Naoe T Jpn J Cancer Res 2000 91 11 1154-1160 FR-901228 induces cell cycle arrest and apoptosis preferentially in malignant lymphoid cells compared to normal hematopoietic cells.
22. 1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE Br J Cancer 2000 83 6 817-825 Describes mechanisms of cell cycle arrest in human tumor cell lines treated with FR-901228.
23. 457844 Histone deacetylase inhibitors in cancer treatment. Vigushin DM, Coombes RC Anti Cancer Drugs 2002 13 1 1-13
24. 461017 Fujisawa Pharmaceutical Co Ltd: Annual report 2002. Fujisawa Pharmaceutical Co Ltd Annual Report 2002 June 26
25. 462248 In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice. Kosugi H, Ito M, Yamamoto Y, Towatari M, Ito M, Ueda R, Saito H, Naoe T Jpn J Cancer Res 2001 92 5 529-536 Synergism of FR-901228 and ATRA on induction of differentiation of human APL cells in vitro and APL tumor xenografts in vivo.
26. 462249 Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Rajgolikar G, Chan KK, Wang HCR Breast Cancer Res Treat 1998 51 1 29-38
27. 462251 Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228. Fecteau KA, Mei J, Wang HCR J Pharmacol Exp Ther 2002 300 3 890-899
28. 462253 Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK et al Clin Cancer Res 2002 8 3 718-728
29. 462255 FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S Exp Cell Res 1998 241 1 126-133
30. 462257 Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Wang R, Brunner T, Zhang L, Shi Y Oncogene 1998 17 12 1503-1508
31. 462261 FR901228 causes mitotic arrest but does not alter microtubule polymerization. Sandor V, Robbins AR, Robey R, Myers T, Sausville E, Bates SE, Sackett DL Anti Cancer Drugs 2000 11 6 445-454
32. 462263 Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR Blood 1999 94 4 1401-1408
33. 462264 Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. Yu X, Guo S, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS J Natl Cancer Inst 2002 94 7 504-513 Describes mechanisms whereby FR-901228 induces apoptosis of human non-small-cell lung cancer cells.
34. 462275 DNA methyltransferase inhibition enhances apoptosis induced by histone deacytelase inhibitors. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA Cancer Res 2001 61 4 1327-1333
35. - symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T J Clin Endocrinol Metab 2001 86 7 3430-3435
36. 462278 Construction of gene therapy vectors targeting thyroid cells: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3′,5′-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. Kitazono M, Chuman Y, Aikou T, Fojo T J Clin Endocrinol Metab 2001 86 2 834-840
37. 462279 Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Kitazono M, Rao VK, Robey R, Aikou T, Bates S, Fojo T, Goldsmith ME Blood 2002 99 6 2248-2251
38. 462280 A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics. Li Z, Chan KK J Pharm Biomed Anal 2000 22 1 33-44
39. 462281 Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment. Richon VM, O'Brien JP Clin Cancer Res 2002 8 3 662-664